original ) (raw )Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy
Joke Baars
Leukemia, 2003
View PDFchevron_right
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
Thomas Elter
Blood, 2008
View PDFchevron_right
Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation
Julia Cruz
Biology of Blood and Marrow Transplantation, 2002
View PDFchevron_right
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
G. Dastoli
Critical Reviews in Oncology/Hematology, 2001
View PDFchevron_right
Rituximab in Hodgkin lymphoma: Is the target always a hit
monika saini
Cancer Treatment Reviews, 2011
View PDFchevron_right
Rituximab used in three cases with relapsed non-Hodgkin's lymphoma
murat elli
Molecular and clinical oncology, 2013
View PDFchevron_right
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease
L.jeffrey Medeiros
Cancer, 2003
View PDFchevron_right
Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral stem cell transplantation
Stephen Schuster
Bone Marrow Transplantation, 1999
View PDFchevron_right
Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
Martin Dyer
Journal of Clinical Oncology, 2009
View PDFchevron_right
Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial
Zhen Fan
2003
View PDFchevron_right
Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review
Paula Marlton
British Journal of Haematology, 2002
View PDFchevron_right
Monoclonal antibody therapy for classical Hodgkin lymphoma
Jan Walewski
Clinical Investigation, 2013
View PDFchevron_right
90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma
Jeffrey White
Proceedings of the National Academy of Sciences of the United States of America, 2015
View PDFchevron_right
Testing of mechanisms of action of rituximab and clinical results in high-risk patients with aggressive CD20+ lymphoma
Vladimir Kotnik
Radiology and Oncology, 2007
View PDFchevron_right
Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin�s lymphoma
Laura Galan
Clinical and Translational Oncology, 2010
View PDFchevron_right
Novel Strategies to Improve Rituximab Efficacy in Non-Hodgkin's Lymphomas
Peertechz Journals
View PDFchevron_right
Rituximab (anti-CD20 monoclonal antibody) in lymphoproliferative malignancies: Tata Memorial experience
Reena Nair
The Journal of the Association of Physicians of India, 2006
View PDFchevron_right
Novel CD20 monoclonal antibodies for lymphoma therapy
Nikhil Mukhi
Journal of Hematology & Oncology, 2012
View PDFchevron_right
Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study
Geir Tjønnfjord
European Journal of Haematology, 2002
View PDFchevron_right
Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma
U. Vitolo
Haematologica, 2001
View PDFchevron_right
Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis
Maulida Ilhamna
Scientific Reports, 2021
View PDFchevron_right
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
Owen O'Connor
British journal of haematology, 2017
View PDFchevron_right
[Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma]
Angel Yepez
Gan to kagaku ryoho. Cancer & chemotherapy, 2002
View PDFchevron_right
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma
Maria Jesús Blanco
View PDFchevron_right
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
Branimir Jaksic
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015
View PDFchevron_right
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
Nam Dang
Blood, 2012
View PDFchevron_right
Anti-CD20 Monoclonal Antibody (Rituximab) for Therapy of Mediastinal CD20-Positive Large B-Cell Non-Hodgkin Lymphoma with a Local Tumor Extension into the Lung of a 10-Year-Old Girl
Stipan Janković
Pediatric Hematology-Oncology, 2003
View PDFchevron_right